Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.


TSXV:VM - Post by User

Comment by lscfaon Apr 22, 2022 4:49pm
167 Views
Post# 34625161

RE:$0.55 buy rating

RE:$0.55 buy rating

Seems overly conservative. Analyst discounts PEA cash flows at 25%/yr (vs 8% PEA and 11.6% by analyst for wholesale model) and then cuts NPV in half again.
 

 

 

PEA

Analyst

AT-NPV

344

135

Discount rate

8%

25%

Further discount

-

50%

Fair value

344

68

Shs o/s 

103.5

103.5

FV/sh

$3.32

$0.66

More shs issued

100

-

FV/sh 

$1.69

$0.66

 



biggdogg wrote: https://voyageurpharmaceuticals.ca/buy-rating-increased-to-0-55-share-fundamental-research-corp/?utm_source=mailpoet&utm_medium=email&utm_campaign=voyageur-minerals-news-update_1

 

<< Previous
Bullboard Posts
Next >>